United Therapeutics (UTHR) Upgraded by BidaskClub to Hold
United Therapeutics (NASDAQ:UTHR) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
Several other equities analysts have also recently weighed in on UTHR. ValuEngine raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a research note on Thursday, October 26th. Cowen reaffirmed a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a research note on Friday, October 27th. Finally, Zacks Investment Research cut shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $136.10.
United Therapeutics (UTHR) opened at $134.17 on Wednesday. The firm has a market cap of $5,760.90, a price-to-earnings ratio of 11.76 and a beta of 1.42. United Therapeutics has a 52 week low of $112.01 and a 52 week high of $169.89.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the company posted $4.23 earnings per share. analysts predict that United Therapeutics will post 12.45 EPS for the current fiscal year.
In other news, CEO Martine A. Rothblatt sold 1,241 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total value of $160,026.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,232 shares of the firm’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $133.32, for a total transaction of $164,250.24. Following the completion of the sale, the chief executive officer now owns 2,301 shares of the company’s stock, valued at approximately $306,769.32. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $2,919,517 over the last three months. Corporate insiders own 7.80% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in UTHR. Quantbot Technologies LP lifted its holdings in shares of United Therapeutics by 537.3% in the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in United Therapeutics during the 3rd quarter valued at about $156,000. Toronto Dominion Bank lifted its holdings in United Therapeutics by 244.7% during the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,351 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new stake in United Therapeutics during the 3rd quarter valued at about $233,000. Finally, TLP Group LLC bought a new stake in United Therapeutics during the 2nd quarter valued at about $246,000. Hedge funds and other institutional investors own 99.94% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “United Therapeutics (UTHR) Upgraded by BidaskClub to Hold” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/united-therapeutics-uthr-upgraded-by-bidaskclub-to-hold/1746490.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.